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 Abstract 
Aims/hypothesis In mammals, the evolutionary conserved family of Mg2+-dependent 
phosphatidate phosphatases (PAP1), involved in phospholipid and triacylglycerol 
synthesis, consists of lipin-1, lipin-2 and lipin-3. While mutations in the murine Lpin1 
gene cause lipodystrophy and its knockdown in mouse 3T3-L1 cells impairs 
adipogenesis, deleterious mutations of human LPIN1 do not affect adipose tissue 
distribution. However, reduced LPIN1 and PAP1 activity has been described in 
participants with type 2 diabetes. We aimed to characterise the roles of all lipin family 
members in human adipose tissue and adipogenesis. 
Methods The expression of the lipin family was analysed in adipose tissue in a cross-
sectional study. Moreover, the effects of lipin small interfering RNA (siRNA)-mediated 
depletion on in vitro human adipogenesis were assessed. 
Results Adipose tissue gene expression of the lipin family is altered in type 2 diabetes. 
Depletion of every lipin family member in a human Simpson–Golabi–Behmel 
syndrome (SGBS) pre-adipocyte cell line, alters expression levels of adipogenic 
transcription factors and lipid biosynthesis genes in early stages of differentiation. 
Lipin-1 knockdown alone causes a 95% depletion of PAP1 activity. Despite the reduced 
PAP1 activity and alterations in early adipogenesis, lipin-silenced cells differentiate and 
accumulate neutral lipids. Even combinatorial knockdown of lipins shows mild effects 
on triacylglycerol accumulation in mature adipocytes. 
Conclusions/interpretation Overall, our data support the hypothesis of alternative 
pathways for triacylglycerol synthesis in human adipocytes under conditions of 
repressed lipin expression. We propose that induction of alternative lipid phosphate 
phosphatases, along with the inhibition of lipid hydrolysis, contributes to the 
maintenance of triacylglycerol content to near normal levels. 
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Abbreviations 
DAG  Diacylglycerol 
DNL  De novo lipogenesis 
ER  Endoplasmic reticulum 
FAO  Fatty acid oxidation 
LPP  Lipid phosphate phosphatases 
ORO  Oil Red O staining 
PAP   Phosphatidate phosphatase 
PPAR  Peroxisome proliferator activated receptor 
SGBS  Simpson–Golabi–Behmel syndrome 
siRNA  Small interfering RNA 
SAT  Subcutaneous adipose tissue 
TAG  Triacylglycerol 
VAT  Visceral adipose tissue 
 Introduction 
Triacylglycerols (TAGs) are neutral lipids that act as the major energy storage 
molecules, repository for fatty acids, and phospholipid precursors [1]. Adipocytes are 
the specialised cells for neutral lipid storage and one of their important physiological 
functions is to buffer the toxicity caused by NEFAs. Excessive calorie intake or genetic 
disorders can lead to lipid deposition in ectopic tissues, impair their function and lead to 
dyslipidaemia, insulin resistance and type 2 diabetes [2-3]. 
Lipins are Mg2+-dependent phosphatidate phosphatases (PAP1) with a central 
role in lipid metabolism, and catalyse the dephosphorylation of phosphatidate to 
diacylglycerol (DAG), which can be (1) acylated to form TAG, or (2) used in 
phospholipids synthesis [4-5]. A second type of PAP activity is mediated by Mg2+-
independent transmembrane lipid phosphate phosphatases (LPPs, also known as PAP2), 
which are thought to regulate signalling properties of phosphatidate and DAG [6]. 
Fungi, nematodes and insects express one lipin, whereas mammals express three 
paralogues called lipin-1, -2 and -3 that exhibit distinct but overlapping expression in 
many mouse and human tissues [5]. Consistent with their key metabolic role, loss of 
lipin function disrupts TAG production, membrane organisation and phospholipid 
synthesis in several model organisms [7]. Interestingly, besides their enzymatic 
functions, lipins also regulate transcription [8-13]. For instance, lipin-1 transcriptional 
co-regulation of the peroxisome proliferator activated receptor (PPAR)A/PPAR 
coactivator 1α axis modulates fatty acid oxidation (FAO) in liver [9]. 
Lpin1 gene was originally identified as the deficient gene causing lipodystrophy, 
insulin resistance, peripheral neuropathy and neonatal fatty liver in the fld (also known 
as Lpin1) mouse model [14]. Loss of lipin-1 in mice blocks adipogenesis at an early 
stage preceding TAG accumulation, suggesting a distinct role of lipin-1 in 
 differentiation [15-16]. Consistently, small interfering RNA (siRNA)-mediated 
silencing of lipin-1 in mouse 3T3-L1 cells potently inhibits adipogenesis [10, 17]. In 
contrast, deleterious mutations in the LPIN1 gene in humans, which lead to recurrent 
rhabdomyolysis in childhood, do not compromise adipose tissue [18]. The basis of this 
difference between mice and humans is unknown; it has been hypothesised that it is due 
to compensation by the other two lipins [18]. Nevertheless, genetic variation in LPIN1 
and LPIN2, and reduced LPIN1 expression levels and PAP1 activity in human adipose 
tissue have been associated with type 2 diabetes [19-25], which suggests a loss of their 
protective role against lipotoxicity. 
While most of the studies have been performed on mice, very little is known on 
the roles of lipin-1 in human adipocyte physiology, while there is virtually no 
information on lipin-2 and -3. This prompted us to investigate the functions of the three 
lipins in type 2 diabetes and in human adipocytes by studying the effects of loss-of-
function. 
 Methods 
Reagents Unless otherwise stated, all reagents were supplied by Sigma-Aldrich 
Corporation (St Louis, MO, USA). Human insulin was purchased from NovoNordisk 
(Bagsværd, Denmark); rosiglitazone from Cayman Chemical (Ann Arbor, MI, USA); 
and cell culture media from Gibco (Thermo Fisher Scientific, Waltham, MS, USA). 
 
Human adipose tissue biopy collection The cross-sectional study has been previously 
described [26, 27]. We used a cohort of 71 participants for the gene expression analysis, 
and of 28 males for protein analysis. They were grouped as: (1) normoweight (BMI 
between 18.50 and 24.99), (2) obesity (BMI ≥25) and (3) obesity with type 2 diabetes 
(hereafter type 2 diabetes). Group characteristics are described in Electronic 
Supplementary Material (ESM) Table 1A and 1B, respectively. Samples were obtained 
at the Joan XXIII University Hospital (Tarragona, Spain). VAT and SAT samples (gene 
expression) and SAT samples (protein expression) were obtained during abdominal 
elective surgical procedures for benign pathologies (cholecystectomy or surgery for 
abdominal hernia). The Ethics Committee approved the study and informed consent was 
obtained from all participants. Participants had no systemic disease other than obesity 
[28] or type 2 diabetes [29]. See ESM Methods for further details. 
 
Cell culture and differentiation Simpson–Golabi–Behmel syndrome (SGBS) cells, a 
well-established system for studies of human adipocyte biology [30, 31], were 
differentiated as described [30], except that 1 nmol/l of insulin, 0.1 µmol/l cortisol, 2 
µmol/l rosiglitazone and 25 nmol/l dexamethasone were used. See ESM Methods for 
detailed information.  
 Adipose-derived stem cells were isolated from adipose tissue (n=3 female donors; age 
(years) 37.4±6.4, BMI (kg/m2) 25.9±3.0) from patients undergoing elective liposuction 
surgery. See ESM Methods for the isolation, proliferation and adipogenic procedure 
details. 
 
Quantification of expression levels Protein content in cell lysates (lysis buffer: 50 
mmol/l HEPES pH 7.4, 150 mmol/l NaCl, 4 mmol/l MgCl2, 1% Triton X-100 and 
protease inhibitors) was quantified by using the bicinchoninic acid assay (Pierce, 
Rockford, IL, USA). See ESM for western blot procedures. Antibodies against lipin 
family members were previously described [17, 32]. Quantitative PCR was performed 
as previously described [28], and expressed relative to cyclophilin A and to control. See 
ESM for detailed information and ESM Table 2B and 2C for commercial reagents. 
 
Cell Fractionation For cell fractionation, SGBS cells were grown and differentiated 
until day 10. Subcellular fractions were obtained by using hypotonic lysis followed by 
high salt extraction of nuclei. See ESM Methods for further details. 
 
Gene silencing Transfections of SGBS cells with siRNA oligonucleotides were carried 
out by using Lipofectamine RNAiMAX transfection reagent (Thermo Fisher Scientific). 
Pre-adipocyte knockdowns were performed as a two-shots transfection of a mix of two 
siRNA duplexes per gene (12.5 nmol/l of each duplex) (see ESM Table 2A): reverse 
transfection at the start of the experiment and forward transfection the day before 
confluence. The non-targeting control concentration depended on total siRNA amount 
of the single and multiple knockdowns. 
 
 Neutral lipid accumulation and metabolism Data were obtained from differentiated 
SGBS cells and normalised by protein content. For TAG analysis, cells were processed 
as previously described [32], except that the supernatant fraction was analysed with the 
Serum Triglyceride Determination kit (Sigma). Glycerol release to cell culture media 
was quantified by using the Free Glycerol Determination Kit (Sigma). Fatty acid and 
glucose incorporation into TAGs, and FAO analysis were performed as previously 
described [33], with slight modifications (see ESM Methods for details). 
 
Enzyme assay Cell lysates (lysis buffer: 50 mmol/l Tris-HCl pH 7.5, 0.25 mol/l 
sucrose, 10 mmol/l 2-mercaptoethanol, protease inhibitors) were subjected to 
centrifugation at 1,000 g for 10 min at 4°C to remove cell debris. Protein concentration 
was determined by the method of Bradford [34] using BSA as a reference protein. 
Preparation of the substrate and measure of PAP activity was as previously described 
[35-37]. See ESM Methods for details. The Mg2+-independent LPP activity was 
measured in the same reaction mixture except that 2 mmol/l EDTA was substituted for 
0.5 mmol/l MgCl2. The Mg2+-dependent PAP1 activity was determined by subtraction 
of LPPs activity from PAP activity. A unit of PAP activity (expressed as units/mg 
protein) was defined as the amount of enzyme catalysing the formation of 1 nmol of 
product/min. 
 
Metabolomic analysis—SGBS cells were grown, transfected with siRNA as explained 
above, and differentiated to day 4. In brief, lipids were extracted from lyophilized 
samples by using dichloromethane/methanol and water. The organic phase (lipidic) was 
collected, dried under a stream of nitrogen, and resuspended in 
acetonitrile/isopropanol/water for untargeted LC-MS analysis. Differentially regulated 
 lipids (p value<0.05 and fold>2) were retained for compound identification by MS/MS 
analyses. See ESM Methods for detailed procedures. 
 
Statistical analysis Statistical analysis was performed by using the SPSS software 
version 15 (Chicago, IL, USA). ANOVA, Kruskal–Wallis, Pearson χ2, Spearman 
correlation and Linear Stepwise Regression tests were performed for the human cohort 
analysis, and the General Linear Model Univariate test and Student T-test for in vitro 
experiments. Statistical power in the cohort analysis was ≥80%. The level of 
significance was set at α=0.05. 
 Results 
Adipose tissue expression levels of the lipin family is altered in type 2 diabetes To 
investigate the roles of lipin paralogues in adipose tissue, we started by examining their 
gene expression in paired abdominal subcutaneous (SAT) and visceral (VAT) adipose 
tissue biopsies. As shown in Fig. 1a–c and ESM Fig. 1a–c, LPIN1 expression was 
reduced in both SAT (p<0.001) and VAT (p=0.021) in the obesity and type 2 diabetes 
groups compared with normoweight. LPIN2 expression was similar among groups. In 
contrast, SAT LPIN3 expression was significantly increased in the type 2 diabetes 
(p=0.018). At the protein level, SAT showed only lipin-1 was downregulated in obesity 
and in type 2 diabetes compared with normoweight (p=0.034) (Fig. 1d–f). 
Correlation analysis showed a negative association of LPIN1 expression levels 
with BMI, HOMA-IR and plasma TAG levels. In contrast, expression of LPIN3 
positively correlates with fasting glucose (SAT) and NEFA (VAT) (Table 1). 
Regression analysis was performed, assessing age and sex as confusing and interacting 
variables, and showed that (1) SAT LPIN1 expression depends negatively on HOMA-
IR (R=0.466, p=0.005, excluded variables: BMI, TAG, age and sex; LPIN1SAT = 
0.37×log10HOMA+0.984), and (2) SAT LPIN3 expression depends positively on 
plasma glucose levels (R=0.414, p=0.002, excluded variables: age and sex; LPIN3SAT = 
1×10[1.202×log10Glucose–0.961]). 
The observed changes of the lipin family expression in type 2 diabetes 
participants may account for the altered PAP1 activity in adipocytes from these patients. 
Moreover, LPIN3 expression is associated with fasting glucose levels. Alterations in 
lipin-3 protein levels in SAT of participants with type 2 diabetes may be masked by its 
presence also in the stromal vascular fraction (data not shown). 
 
 The three lipin family members have a role in early human adipogenesis Next, we 
examined the expression of lipins during adipogenesis. Lipin-1 was induced, and lipin-2 
and lipin-3 levels were present along SGBS adipogenesis with slight variation (Fig. 
2a,b). Thus, SGBS adipocytes, similar to differentiated adipose-derived stem cells 
(ESM Fig. 1d), express the three lipin paralogues. Finally, under baseline conditions, 
the three lipins partitioned between the cytosolic, intranuclear and membrane-bound 
forms in SGBS adipocytes (ESM Fig. 1e). 
To address the effects of decreased PAP1 activity on adipogenesis, we depleted 
each lipin member prior to the induction of adipogenesis in SGBS pre-adipocytes (by 
using siRNA; see Methods and Fig. 2c). Cells were analysed at day four after 
differentiation to assess adipogenic early events. Protein expression analysis was used 
to confirm knockdowns and evaluate possible compensatory mechanisms among lipins. 
Lipin-1 depleted cells responded by compensatory upregulation of lipin-2 protein (Fig. 
2d and ESM Fig. 1f), but not LPIN2 transcript levels (data not shown). Conversely, 
single lipin-2 and lipin-3 knockdowns led to lower protein levels of the other family 
members (Fig. 2d). Analysis of PAP1 activity showed that lipin-1 accounted for almost 
all PAP1 activity (lipin-1-depleted cells showed 5% of PAP1 activity in the control), 
with lipin-2 and lipin-3 single knockdowns reducing it to 49% and 61%, respectively 
(Fig. 2e). 
Next, we analysed incorporation of fatty acids and glucose into TAGs. While 
esterification of fatty acids was downregulated in lipin-1- and lipin-2-depleted cells, 
glucose incorporation into TAGs decreased in all three lipin-depleted cells (Fig. 2f). 
Finally, we analysed the expression levels of transcription factors that promote early 
adipogenesis. CEBPA was downregulated in cells depleted of any lipin family member, 
and CEBPB was decreased upon lipin-2 deficiency (Fig. 2g). Under these conditions, 
 gene expression of two key transcription factors regulated by CCAAT/enhancer binding 
proteins, PPARG and SREBP1 were downregulated (Fig. 2g), and also at the protein 
level (ESM Fig. 2a,b). CEBPD showed a significant upregulation in cells depleted of 
any lipin family member (Fig. 2g), probably due to the triggering of a compensation 
mechanism. 
Given the role of lipins in neutral lipid biosynthesis, we next explored 
expression of lipogenic genes. The expression of these genes was significantly 
downregulated in cells depleted of any lipin family member (Fig. 2h). In contrast, 
glycerol-3-phosphate acyltransferase was significantly upregulated in the lipin-1 and 
lipin-2 knockdowns (Fig. 2h). Lipid quantification by mass spectrometry showed that, 
among the lipid species that were altered, the levels of most DAG (ESM Fig. 2c) and 
TAG (ESM Fig. 2d) species were downregulated in cells depleted of any lipin 
compared with controls. Interestingly, phosphatidate levels did not change (data not 
shown). 
Overall, despite the crosstalk between lipin family members, lipin-1 silencing 
leads to a 95% depletion of PAP1 activity. However, our results point to a role of all 
three members on early stages of human adipogenesis. 
 
Single lipin silencing does not block TAG accumulation in fully differentiated 
adipocytes Next, we analysed the effects of lipin silencing in SGBS pre-adipocytes on 
late adipogenesis. Similarly to the above experiments, we depleted each lipin member 
prior to induction of adipogenesis in SGBS pre-adipocytes, and cells were analysed at 
day 10 after differentiation (Fig. 3a), where protein downregulation of lipins still 
persisted (Fig. 3b and ESM Fig. 3a). 
 At day 10, lipin-1 depleted cells still responded by compensatory upregulation of 
lipin-2 protein (Fig. 3b and ESM Fig. 3a). Additionally, both single lipin-2 and lipin-3 
knockdowns led to lower protein levels of the other lipins. PAP1 activity analysis 
showed that lipin-1 accounted for almost all PAP1 activity (lipin-1-depleted cells 
showed 3% of the activity in the control). Lipin-2 and lipin-3 single knockdowns 
reduced PAP1 activity only slightly (84% and 74%, respectively) (Fig. 3c). 
Next, we assessed neutral lipid accumulation. Depletion of any lipin triggered a 
slight reduction (15% to 34%) in TAG accumulation (Fig. 3d). Expression of key 
transcription factors for lipogenesis (ESM Fig. 3a,b) and genes of lipid biosynthesis 
(ESM Fig. 3c) were altered to a lesser extent compared with the effects observed at day 
four. 
Finally, fatty acid esterification into TAGs and α-glycerophosphate synthesis/de 
novo lipogenesis (DNL) were downregulated in cells depleted of any lipin (Fig. 3e). 
Compared with day 4, lipin-3 depletion also showed reduced fatty acid esterification 
into TAGs at day 10. 
Overall, the effects of lipin knockdown were mild on fully differentiated 
adipocytes suggesting that cells overcame the initial impairment of lipid gene 
expression. This may be due to the existence of enough remnant protein amounts of 
lipins, although PAP1 activity at day 10 was still almost absent in the lipin-1 
knockdowns. 
 
Combinatorial silencing of lipins does not further alter the phenotype of fully 
differentiated adipocytes We then asked whether compensation by other lipin family 
members might help cells to recover the initial alterations shown at day 4 after 
adipogenesis. We used a combinatorial knockdown to deplete combinations of two of 
 the three lipins in SGBS pre-adipocytes (see Methods), and analysed cells at day 10 of 
differentiation (as in Fig. 3a). 
Double lipin-1 and lipin-3 knockdowns led to an upregulation of lipin-2 protein 
levels (Fig. 4a and ESM Fig. 4). This compensatory pattern hindered the efficiency of 
lipin-2 knockdown in the double (lipin-1 and -2) and triple knockdown cells. 
Nevertheless, PAP1 activity in the triple knockdown was residual compared with the 
control (0.18±0.31 vs 39.29±3.42 nmol min–1 mg–1). 
Despite the almost complete lack of PAP1 activity, neutral lipid accumulation 
was not totally compromised in the triple knockdown (Fig. 4b). This is in agreement 
with the fact that deleterious mutations in LPIN1 do not affect adipose tissue 
development in humans, and it suggests that it is unlikely to be due to a compensatory 
upregulation of lipin-2 (Fig. 2d), since the double lipin-1 and -2 knockdown shows a 
similar reduction in the content of neutral lipids (Fig. 3d and 4b). 
Moreover, depletion of the three lipins did not significantly affect fatty acid 
esterification into TAGs and only slightly downregulated α-glycerophosphate 
synthesis/DNL (Fig. 4c), pointing to an improvement compared with day 4 (day 4 
incorporation of fatty acids: 0.52 ± 0.35, p=0.006, and of glucose: 0.32 ± 0.15, p<0.001, 
fold over the control level). 
 
Consumption of TAGs is reduced in lipin-depleted SGBS adipocytes Lipid droplets 
accumulate neutral lipids in a dynamic manner, with a balance among lipid 
biosynthesis, lipid hydrolysis and FAO in mitochondria. To test whether cells protect 
intracellular lipids by reducing its consumption, we analysed the rates of palmitate 
oxidation. The results show similar FAO rates in the control, single (Fig. 5a) and triple 
knockdown (Fig. 5b). In contrast, levels of glycerol release were downregulated 
 compared with controls in the single (Fig. 5c), and in all combinatorial knockdowns 
(Fig. 5d). Thus, reduced consumption may contribute to the accumulation of neutral 
lipids in lipin-depleted adipocytes. 
 
The LPP family is upregulated under conditions of repressed lipin expression Next, 
we tested whether the Mg2+-independent LPPs could provide an alternative pathway for 
DAG synthesis. LPP activity was highly induced in the lipin-1 single knockdown 
(3.50±1.18-fold increase over control levels) (Fig. 6a), and in the triple knockdown 
(2.74±0.97-fold increase) at day 10 of differentiation (Fig. 6b). 
Moreover, the expression of LPP3 (also known as Plpp3/PPAP2B) was 
upregulated in the single (Fig. 6c) and in the combinatorial lipin knockdowns at day 10 
(Fig. 6d) and, similarly to lipogenic genes, upregulation was higher at day four (ESM 
Fig. 5a). This was confirmed by using other commercial sources of lipin-1 siRNA 
(ESM Fig. 5b) and analysing LPP expression at day four of differentiation (ESM Fig. 
5c). 
Propranolol, a nonspecific ß-blocker, is an effective PAP1 activity inhibitor and 
modestly effective as LPP inhibitor, with the LPP3 isoform being more sensitive to 
inhibition [36]. Propranolol treatment during adipogenesis (Fig. 6e) altered lipogenic 
gene expression (Fig. 6f) and blocked lipid droplet formation in SGBS adipocytes 
(ESM Fig. 5d). 
 Discussion 
Herein we have addressed the contribution of the lipin paralogues to human 
adipogenesis. Decreased lipin expression levels and PAP1 activity in adipose tissue 
have been linked with insulin resistance [23-25]. In our cohort, adipose tissue 
expression confirmed that lipin-1 is altered in type 2 diabetes and that LPIN1 is 
negatively associated with insulin resistance. Moreover, we show that LPIN3 transcript 
levels are positively related with fasting glucose levels. This prompted us to analyse 
separately the effects of gene silencing of each lipin paralogue in adipogenesis. 
Previous studies have established that lipin-1 plays a major role in fat 
metabolism in rodents, with lipin-1 deficiency causing lipodystrophy features in mice 
and rats [14, 38]. The role of lipins in human adipogenesis is still undefined: mutations 
in the LPIN1 gene have not yet been detected in human lipodystrophy [39-40]. 
Moreover, deleterious LPIN1 mutations cause paediatric rhabdomyolysis while fat 
distribution, average weight and plasma biochemical variables are normal [18]. Our data 
suggest that the lack of an essential role for PAP1 activity in human adipogenesis is not 
due to compensation by lipin-2 or lipin-3. We find that the triple lipin silencing in 
SGBS pre-adipocytes maintains the ability to incorporate fatty acids into TAG and 
accumulate neutral lipids despite loss of nearly all PAP1 activity. 
SGBS pre-adipocytes are differentiated in the absence of serum and, therefore, 
neutral lipids should be obtained from DNL. Besides, although glyceroneogenesis is the 
major pathway for glycerol synthesis in the mature adipocyte [41], during adipogenesis 
glycolysis may account for an important source of α-glycerophosphate. Thus, glucose 
incorporation into TAGs may account for DNL, but also for α-glycerophosphate 
synthesis via glyceroneogenesis and glycolysis. Downregulated α-glycerophosphate 
synthesis/DNL points to broader effects of lipin silencing other than TAG synthesis. 
 Moreover, the putative intranuclear roles of lipin-1, -2 and -3 in SGBS adipocytes add 
some complexity to the above. 
The lipin family members cooperate for optimal PAP activity in mouse adipose 
tissue [42], liver [43-44], brain [43] and human primary myoblasts [45]. Our data show 
that human lipin-1 accounts for most PAP1 activity in SGBS adipocytes and that 
upregulation of lipin-2 in lipin-1-depleted cells does not compensate for PAP1 activity. 
By contrast, downregulation of PAP1 activity in lipin-2 and lipin-3 single knockdowns 
cannot be fully attributed to their own depletion since they also downregulate lipin-1. 
Activation of non-lipin compensatory pathways may also mask the lipin 
phenotypes. Nevertheless, (1) we found no evidence, at the mRNA level, of 
upregulation of the monoacylglycerol O-acyltransferase pathway that can generate 
DAG from monoacylglycerol [46-47] (data not shown); and (2) cholesteryl esters levels 
are likely not upregulated since the effect of lipin knockdown on neutral lipid content 
looks similar by Oil Red O staining (ORO) and TAG content (ORO: 0.76 ± 0.06, and 
TAG: 0.85 ± 0.13 in the lipin-1 knockdown, and ORO: 0.74 ± 0.12, and TAG: 0.54 ± 
0.33 in the triple lipin knockdown, compared with the control set as 1). In contrast, LPP 
activity was induced in the lipin knockdowns, possibly due to an earlier upregulation of 
their transcript levels (observed by day four). Moreover, inhibition of both lipins and 
LPPs with propranolol completely blocked lipid droplet formation, although this fact 
must be taken with caution because of the non-specificity of this compound. LPPs 
hydrolyse phosphatidate as well as different substrates, and act on the outer surface of 
plasma membrane and in the luminal surface of endoplasmic reticulum (ER) and Golgi 
membranes [6] and thus, it is not clear if they can have access to the phosphatidate 
formed from glycerol phosphate and acyl-CoA. However, in yeast, TAG synthesised 
 both in the cytosolic and luminal leaflets of the ER membranes are efficiently packed 
into lipid droplets [48]. 
Another strategy to protect the lipid storage when glycerolipid synthesis is 
compromised might be downregulation of lipid hydrolysis and FAO. Lipin-1 regulates 
basal lipolysis [46], and modulates FAO transcript expression levels [8]. We show that 
all combinatorial knockdowns of lipins downregulate basal lipolysis to a greater extent 
than reduction of neutral lipid content. 
In summary, we confirm that adipose tissue expression of the lipin family is 
altered in type 2 diabetes. Furthermore, loss of nearly all PAP1 activity, due to 
combined lipin-1, -2 and -3 knockdown, has only mild effects on final adipogenesis and 
lipid accumulation in SGBS cells. Conversely, lipin-2 and lipin-3 may contribute little 
to total PAP activity, but still play a role in early adipogenesis. Our results suggest a 
compensation strategy to accumulate near normal neutral lipid levels, activating other 
pathways (such as LPPs) and inhibiting TAG hydrolysis. More work is clearly required 
to decipher whether LPPs or other unknown pathways may compensate lack of PAP1 
activity. 
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 Table 1 Correlation analysis in abdominal SAT and VAT adipose tissue biopsies 
from 71 participants 
Variable SAT  VAT 
LPIN1 LPIN2 LPIN3 LPIN1 LPIN2 LPIN3 
BMI -0.349**  -0.021  0.220   -0.283† -0.091  0.034  
HOMA-
IR 
-0.471**  -0.104 -0.006   -0.329*  -0.139 -0.006 
Glucose -0.349** 0.253† 0.357*
* 
 -0.119 0.189  0.298†  
Insulin -0.522***  -0.169  -0.039   -0.340**  -0.179  0.017  
Triacygl
ycerol 
-0.319**  -0.018  0.072   -0.202  0.131  0.238  
NEFA -0.095  0.129  0.128   -0.029  0.125  0.336**  
Glycerol -0.188  -0.105  0.144   -0.113  0.097  0.274†  
 
Spearman coefficient of the correlation analysis is shown. *p<0.05, **p<0.01, 
***p<0.001 
Where statistical power is lower than 80%: †p<0.01 
  
  
Fig. 1 Altered expression of the lipin family in type 2 diabetes adipose tissue. 
Participants were grouped by BMI and type 2 diabetes (T2D). (a–c) mRNA expression 
relative to cyclophilin A and to a calibrator that consisted of a mix of mRNA samples 
(n=17, 43 and 11), and (d–f) protein expression normalised to actin (n=9, 10 and 9) 
were quantified in human abdominal subcutaneous adipose tissue. Data represent mean 
± SD; *p<0.05, **p<0.01, ***p<0.001 vs normoweight; ANOVA and Kruskal–Wallis 
tests 
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Fig. 2 Single knockdowns of lipins in SGBS pre-adipocytes. SGBS pre-adipocytes 
were induced to differentiate, and mRNA (a) and protein (b) levels were analysed 
during adipogenesis at the given time points (n=3). Data represent mean ± SD of fold 
induction over day 0. (c) Knockdowns of single lipin members were performed in pre-
adipocytes, adipogenesis was induced (day 0) and cells were collected at day 4. (d) 
Lipin protein levels (n=7), (e) PAP1 activity (control: 23.10±5.12 nmol min–1 mg–1) 
(n=3), (f) fatty acid (FA) and glucose incorporation into TAGs (control, fatty acids: 
220.8±185.7 arbitrary units TAG/µg protein, glucose: 3.47±6.30 arbitrary units TAG/µg 
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 protein) (n=3), and mRNA levels of (g) early adipogenic transcription factors (n=3), and 
(h) lipogenic genes (n=3) were analysed. Gene expression is expressed relative to 
cyclophilin 1A and to non-targeting control. Protein expression is normalised to actin 
levels. Data represent mean ± SD of fold increase over non-targeting controls (set as 1). 
*p<0.05, **p<0.01, ***p<0.001, General Lineal Model Univariate test. (a, b) White 
squares, LPIN1; grey squares, LPIN2; black squares, LPIN3; (d–h) white bars, LPIN1 
knockdown; grey bars, LPIN2 knockdown; black bars, LPIN3 knockdown 
  
  
Fig. 3 Fully differentiation of lipin-depleted SGBS pre-adipocytes. (a) Knockdowns 
of single lipin members were performed in pre-adipocytes, adipogenesis was induced 
(day 0), and cells were collected at day 10. (b) Lipin protein levels (n=3), (c) PAP1 
activity (control: 38.88±1.38 nmol min–1 mg–1) (n=3), (d) total TAG content (control: 
110.86±37.29 mmol l–1 mg–1) (n=3), and (e) fatty acid (FA) and glucose incorporation 
into TAGs (control, fatty acids: 740.6±292.3 AU TAG/µg protein, glucose: 3.73±2.60 
AU TAG/µg protein) (n=3) were analysed. Data represent mean ± SD of fold increase 
over non-targeting controls (set as 1); *p<0.05, **p<0.01, ***p<0.001; General Lineal 
Model Univariate test. White bars, LPIN1 knockdown; grey bars, LPIN2 knockdown; 
black bars, LPIN3 knockdown 
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Fig. 4 Combinatorial depletion of lipins in SGBS pre-adipocytes after full 
differentiation. Multiple knockdowns of lipin members were performed in pre-
adipocytes, adipogenesis was induced (day 0) and cells were collected at day 10. (a) 
Lipin protein levels (n=3–6), (b) total TAG content (controls: 71.11±36.40 and 
101.79±76.15 mmol l–1 mg–1 for double and triple knockdowns, respectively) (n=5), and 
(c) fatty acid (FA) and glucose incorporation into TAGs in the triple knockdown 
(control, fatty acids: 493.4±226.4 arbitrary units TAG/µg protein, glucose: 3.51±2.26 
arbitrary units TAG/µg protein) (n=3) were analysed. Data represent mean ± SD of fold 
increase over non-targeting controls (set as 1); *p<0.05, ***p<0.001; General Lineal 
Model Univariate test. White bars, LPIN1 and LPIN2 knockdown; light grey bars, 
LPIN1 and LPIN3 knockdown; dark grey bars, LPIN2 and LPIN3 knockdown; black 
bars, triple knockdown 
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Fig. 5 Consumption of neutral lipids in fully differentiated lipin-depleted SGBS pre-
adipocytes. Knockdown of single, double and triple lipin family members was 
performed in pre-adipocytes, adipogenesis was induced (day 0) and cells were collected 
at day 10. Palmitate oxidation rates in (a) single (control: 0.77±0.37 nmol h–1 mg–1) 
(n=3), and (b) triple knockdowns (control: 0.63±0.28 nmol h–1 mg–1) (n=3); glycerol 
release in (c) single (control: 0.42±0.12 mmol l–1 mg–1) (n=3), and (d) combinatorial 
knockdowns (controls, double: 0.36±0.21, and triple: 0.21±0.07 mmol l–1 mg–1) (n=5) 
were analysed. Data represent mean ± SD of fold increase over non-targeting controls 
(set as 1); **p<0.01, ***p<0.001; General Lineal Model Univariate test. (a, c) White 
bars, LPIN1 knockdown; grey bars, LPIN2 knockdown; black bars, LPIN3 knockdown; 
(b, d) white bars, LPIN1 and LPIN2 double knockdown; light grey bars, LPIN1 and 
LPIN3 double knockdown; dark grey bars, LPIN2 and LPIN3 double knockdown; black 
bars, triple knockdown 
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Fig. 6 Induction of the LPP family under conditions of repressed lipin expression. 
Knockdowns of single, double and triple lipin family members were performed in pre-
adipocytes, adipogenesis was induced (day 0) and cells were collected at day 10. LPP 
activity in (a) the single (control: 6.01±0.60 nmol min–1 mg–1) (n=3) and (b) triple 
knockdowns (control: 4.82±0.53 nmol min–1 mg–1) (n=3), and expression levels of the 
LPP family in (c) the single (n=7) and (d) combinatorial knockdowns (n=4–7) were 
analysed. (e) SGBS pre-adipocytes were induced to differentiate in presence of 100 
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 µmol/l of propranolol (PrPol). (f) mRNA levels of lipogenic genes were analysed (n=3). 
Data represent mean ± SD of fold increase over non-targeting controls (a–d) or non-
treated control (f); *p<0.05, **p<0.01, ***p<0.001; General Lineal Model Univariate 
test. (a, c) White bars, LPIN1 knockdown; grey bars, LPIN2 knockdown; black bars, 
LPIN3 knockdown; (b, d) white bars, LPIN1 and LPIN2 double knockdown; light grey 
bars, LPIN1 and LPIN3 double knockdown; dark grey bars, LPIN2 and LPIN3 double 
knockdown; black bars, triple knockdown; (f) white bars, propranolol 
 
 
ESM Methods 
 
Human	adipose	tissue	biopy	collection		
Selection of patients— For the gene expression study, a group of 71 participants was 
recruited at Joan XXIII University Hospital (Tarragona, Spain) and Sant Pau i Santa 
Tecla Hospital (Tarragona, Spain). All participants were of Caucasian origin and 
reported that their body weight had been stable for at least 3 months before the study. 
They had no systemic disease other than obesity or type 2 diabetes, and all had been 
free of any infections in the month before the study. Liver and renal diseases were 
specifically excluded by biochemical workup. 
The study included 17 normoweight, 43 individuals with obesity, and 11 individuals 
with type 2 diabetes, matched for age and gender (ESM Table 1A). Participants were 
classified by BMI according to the World Health Organization criteria [1]. Eleven 
patients were classified as having type 2 diabetes according to the American Diabetes 
Association criteria [2]. Variability in metabolic control was assessed by stable glycated 
haemoglobin A1c values during the previous 6 months. No patients were being treated 
with thiazolidinedione. Pharmacological treatment of the patients with type 2 diabetes 
was as follows: insulin, 9.1%; oral hypoglycaemic agents, 54.5%; statins, 63.6%; blood 
pressure- lowering agents, 54.5%. 
Sample size was calculated, based in a previous study [3], to achieve a difference in 
normalized gene expression levels between the studied groups of 0.3 or greater with a 
confidence level of 95% and a statistical power of 80%. 
Age and sex were assessed as interaction and confusing variables in the regression 
analysis. The global signification test was used to analyse interactions and for proposing 
the reference model. Residual analysis was performed to evaluate the models and data 
exclusion. The final regression model was chosen by comparing reduced models with 
the reference model.  
For the protein expression levels of the lipin family, a group of 28 male participants was 
recruited at Joan XXIII University Hospital (Tarragona, Spain). The study included 9 
normoweight, 10 individuals with obesity, and 9 individuals with type 2 diabetes, 
matched for age (ESM Table 1B). 
 
Anthropometric measurements— Height was measured to the nearest 0.5 cm and body 
weight to the nearest 0.1 kg. BMI was calculated as weight (kilograms) divided by 
height (meters) squared. Waist circumference was measured midway between the 
lowest rib margin and the iliac crest. 
 
Collection and processing of samples— VAT (omental) and SAT (anterior abdominal 
wall) samples were obtained from all individuals for the gene expression analysis, and 
SAT samples for the protein expression analysis. Samples were obtained during 
abdominal elective surgical procedures (cholecystectomy or surgery for abdominal 
hernia). All patients had fasted overnight. Blood samples were collected before the 
surgical procedure from the antecubital vein: 20 ml of blood with EDTA (1 mg/ml), and 
10 ml of blood in silicone tubes. Fifteen millilitres of collected blood were used for the 
separation of plasma. Plasma and serum samples were stored at -80 C until analytical 
measurements were performed. Five millilitres of blood with EDTA were used to 
determine glycated haemoglobin A1c. Adipose tissue samples were collected, washed 
in 1X PBS, immediately frozen in liquid nitrogen, and stored at -80 C. 
Analytical methods— Plasma glucose, cholesterol, and triacylglycerol levels were 
determined in an autoanalyzer (Hitachi 737; Roche Molecular Bio- chemicals, Marburg, 
Germany) using the standard enzyme methods. High-density lipoprotein (HDL) 
cholesterol was quantified after precipitation with polyethylene glycol (PEG-6000) at 
room temperature. Non-esterified free fat acid (NEFA) serum levels were determined in 
an autoanalyzer (Advia 1200; Siemens AG, Munich, Germany) using an enzymatic 
method developed by Wako Chemicals (Neuss, Germany). Plasma glycerol levels were 
analyzed by using a free glycerol determination kit, a quantitative enzymatic 
determination assay (Sigma-Aldrich Corp., St. Louis, MO). Intra- and interassay 
coefficients of variation were less than 6% and less than 9.1%, respectively. Plasma 
insulin was determined by RIA (Coat-A-Count insulin; Diagnostic Products Corp., Los 
Angeles, CA) in all participants, except in insulin-treated type 2 diabetes patients. The 
homeostasis model assessment of insulin resistance (HOMA-IR) was determined as 
[glucose (mmol/l) x insulin (mIU/l)]/22.5 [4].  
 
Cell	culture	and	differentiation		
Differentiation of SGBS cells— Preadipocytes were grown in serum-containing medium 
(DMEM/F12 supplemented with 10% foetal bovine serum, 33 µmol/l biotin, 17 µmol/l 
pantothenate and antibiotics) in a humidified 37 °C incubator with 5% CO2, until 
reaching confluence. Cells were seeded at 25,000 cells per cm2 and reached confluence 
in three days. To induce adipose differentiation cells were repeatedly washed with PBS 
buffer and cultured for four days in serum-free, basal medium supplemented with 33 
µmol/l biotin, 17 µmol/l pantothenate, 1 nmol/l insulin, 200 pmol/l triiodothyronine, 0.1 
µmol/l cortisol, 0.01 mg/ml transferrin, 0.5 mmol/l IBMX, 2 µmol/l rosiglitazone and 
25 nmol/l dexamethasone (differentiation medium). Cells were cultured in adipocyte 
maintenance medium for one week (differentiation medium without IBMX, 
dexamethasone and rosiglitazone). The medium was changed twice a week. 
 
Human adipose stem cell isolation—All tissues were obtained from patients undergoing 
elective liposuction surgery. Adipose-derived stem cells (ASC) were isolated from 
adipose tissue (n=3 female donors; age (years) 37.4±6.4, BMI (kg/m2) 25.9±3.0), 
according to published protocols [5]. Briefly, ASC were obtained from washed 
lipoaspirate tissues by collagenase digestion as explained previously, from the Biobank	of	the	Joan	XXIII	University	Hospital. The resulting SVF cells were cultured in stromal 
medium consisting of Dulbecco's modified Eagle's medium (DMEM)/F12, 10% fetal 
bovine serum (FBS), plus antibiotics at 37 °C, 5% CO2 overnight. The following day, 
the ASC were rinsed with warm PBS and maintained until 80–90% confluent. The ASC 
cultures were collected by trypsin digestion and aliquots of 106 cells cryopreserved in 
liquid nitrogen until required for experimentation. 
Thawed ASC cells were transferred to culture vessels at a density of 5x103 cells/cm2 in 
preadipocyte medium (low glucose DMEM supplemented with 10% FBS, 15 mmol/l 
HEPES, 2.5 ng/ml Fibroblast growth factor-2, 33 µmol/l biotin, 17 µmol/l pantothenate 
and antibiotics). The cells were maintained in a humidified tissue culture incubator at 37 
°C with 5% CO2. The medium was replaced every second day until the cells reached 
80% confluence. Cells were collected by trypsin digestion for inducing adipogenic 
differentiation. 
 
Differentiation of ASCs— The ASCs were used at passage 5. To induce adipogenesis, 
confluent cultures of ASCs were cultured for 2 days in adipocyte differentiation 
medium (DMEM/F-12 supplemented with 10% FBS, 5 µmol/l rosiglitazone, 1 nmol/l 
dexamethasone, 0.5 mmol/l 1-methyl-3-isobutylxanthine (IBMX), 0.01 mg/ml 
transferrin, 1 nmol/l human insulin, 33 µmol/l biotin, 17 µmol/l pantothenate and 
antibiotics). The induced cells were re-fed every 3 days with adipocyte maintenance 
medium (adipocyte differentiation medium without IBMX, and dexamethasone), during 
12 days.  
 
Quantification	of	expression	levels		
qPCR—Total RNA was extracted by using an RNeasy Lipid Tissue Midi Kit (total 
adipose tissue) and RNeasy Tissue Mini Kit (SGBS cells) (QIAGEN, Germantown, 
MD, USA). Total RNA was transcribed to cDNA by using a High-Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems, LifeTechnologies Corporation). Real 
time qPCR analysis was performed with duplicates on a 7900HT Fast Real-Time PCR 
System using hydrolysis probes (Applied Biosystems, ESM Table 2C). SDS software 
2.3 and RQ Manager 1.2 (Applied Biosystems) were used to analyse the results with the 
comparative quantification cycle (Cq) method (2-ΔΔCq), and cyclophilin A as reference 
gene. For the human cohort analysis, samples from different groups were randomised at 
every qPCR run. 
 
Western blot analysis— 10 µg of total protein per lane were resolved by electrophoresis 
in 8 to 12% SDS–PAGE, transferred to nitrocellulose membranes (Whatman), blocked 
in either 5% non-fat dry milk in PBS containing 0.01% Tween 20 or following 
manufacturer´s recommendations for 1 h at room temperature, incubated with the 
primary antibody overnight at 4 °C and secondary for 1 h. The western blots were 
developed with Super-Signal West Femto Maximum Sensitivity Substrate (Pierce). 
Images were quantified by using ImageJ v.1.48 (Wayne Rasband, National Institutes of 
Health, USA). Actin and GAPDH protein levels were used for normalisation. 
 
Cell Fractionation 
For cell fractionation, cells were processed as described previously [6], with some 
modifications. The whole process was performed in ice and centrifugations were 
performed at 16,000 x g and 4˚C. Mainly, SGBS cells were grown and differentiated in 
two wells from 6-well plates, washed with PBS, scrapped in 75 µl of 10 mmol/l Tris-
HCl (pH 7.4), 0.2 mmol/l AEBSF, 1.5 mmol/l MgCl2, 10 mmol/l NaCl, 0.5 mmol/l 
dithiothreitol (DTT). Lysed cells were incubated in ice for 15 minutes vortex mixed, 
and centrifuged 10 seconds. The supernatant was kept as cytosolic fraction and the 
pellet was resuspended in 20 mmol/l Tris-HCl (pH 7.4), 25% glycerol, 0.2 mmol/l 
AEBSF, 1.5 mmol/l MgCl2, 420 mmol/l NaCl, 0.5 mmol/l DTT, 0.2 mmol/l EDTA. The 
lysate was incubated in ice for 20 minutes and centrifuged 2 minutes. The supernatant 
was kept as nuclear fraction and the pellet was resuspended in H2O as membrane bound 
proteins. 
 
Neutral	lipid	accumulation	and	metabolism		
Fatty acid and glucose incorporation into TAGs was measured by incubating adipocytes 
for 16 h at 37°C in serum-free medium containing 0.5 mmol/l palmitate and 1 µCi/ml 
[1-14C] palmitate bound to 1% bovine serum albumin (BSA) or 5 mmol/l glucose and 1 
µCi/ml [1-14C] glucose. Cells were then washed in PBS and lipids were extracted and 
separated by TLC to measure the incorporation of labelled fatty acid into TAGs, as 
described [7]. Data are expressed as arbitrary units normalizaed by protein content. For 
FAO analysis, adipocytes were washed in KRBH 0.1% BSA, preincubated at 37 ºC for 
30 min in KRBH 1% BSA, and washed again in KRBH 0.1% BSA. Cells were then 
incubated for 4 h at 37 ºC with fresh KRBH containing 5 mmol/l glucose and 0.5 
mmol/l carnitine plus 0.25 mmol/l palmitate and 1 µCi/ml [1-14C]palmitate bound to 
1% BSA. Palmitate oxidation to CO2 measurements were performed as previously 
described [7], and expressed as nmol of CO2 h-1 mg-1 of protein. 
 
Enzyme	assay		
The radioactive substrate [32P]phosphatidate was enzymatically synthesized from 1,2-
dioleoyl-sn-glycerol and [γ-32P]ATP with Escherichia coli diacylglycerol kinase. PAP 
activity was measured with cell extracts at 37 C for 20 min in a total volume of 100 µl 
containing 50 mmol/l Tris-HCl (pH 7.5), 0.5 mmol/l MgCl2, 10 mmol/l 2-
mercaptoethanol, 0.2 mmol/l [32P]phosphatidate (5,000 cpm/nmol), and 2 mmol/l 
Triton X-100.  
 
Metabolomic	analysis	
SGBS cells were grown in 6-well plates, transfected with siRNA as explained above, 
and differentiated to day 4. Three wells from a 6-well plate were used per condition, and 
cells were washed with 1X phosphate buffer saline and collected by scrapping with 355 
µl of methanol. Collected cells were sonicated, and an aliquot of 40 µl was used for 
protein quantification. The remaining volume was frozen and kept at -80 C until the 
analysis. Four replicas were performed.  
 
Lipid extraction method— Lipids were extracted from lyophilized samples by adding 
570 µl of a cold mixture of dichloromethane/methanol (2:1 v/v).  The resulting 
suspension was vortexed and bath-sonicated for 5 min. We subsequently added 120 µl 
of cold water, vortex samples again and organic and aqueous layers were allowed to 
equilibrate for 10 min at room temperature. Cell lysates were centrifuged (15,000 rpm, 
15 min at 4 C), and the organic phase (lipidic) was collected for drying under a stream 
of nitrogen. Lipid pellets were resuspended in 300 µl of acetonitrile/isopropanol/water 
(65:30:5 v/v) for LC-MS analysis. 100 µl of culture media was lyophilized and 
subsequently resuspended in dichloromethane/methanol (2:1 v/v) following the same 
procedure as that used for cells, with the exception that lipid pellets were resuspended in 
200 µl (acetonitrile: isopropanol: water (65:30:5 v/v). 
 
LC/MS analysis— Untargeted LC/MS analyses were performed using an UHPLC 
system (1200 series, Agilent Technologies) coupled to a 6550 ESI-QTOF MS (Agilent 
Technologies) operating in positive (ESI+) or negative (ESI–) electrospray ionization 
mode. Lipids were separated by reverse phase chromatography with an Acquity UPLC 
C8 column (150 x 2.1 mm, 1.8 µm). Mobile phase A = water/acetonitrile (60:40) (10 
mmol/l ammonium formate and 0.1% formic acid) and B = isopropanol/acetonitrile 
(95:5) (10 mmol/l ammonium formate, 0.1% formic acid and 0.1% H2O). Solvent 
modifiers, such as 0.1% formic acid and 10 mmol/l ammonium formate, were used to 
enhance ionization, as well as to improve the LC resolution in both positive and 
negative ionization modes. The elution gradient started at 32% B (time 0–1 min), 
increased to 60% of B (time 1–4 min) and increased again to 100% B over 11 min (time 
4–15 min). The injection volume was 2 µl for cell lipids and 5 µl for media lipids. ESI 
conditions: gas temperature, 150 C; drying gas, 13 l/min; nebulizer, 35 psig; 
fragmentor, 150 V; and skimmer, 65 V. The instrument was set to work over the m/z 
range 50–1200 with an acquisition rate of 3 spectra/sec. For compound identification, 
MS/MS analyses were performed in targeted mode, and the instrument set to acquire 
spectra over the m/z range 50–1000, with a default iso width (the width at half-
maximum of the quadrupole mass bandpass used during MS/MS precursor isolation) of 
4 m/z. The collision energy was fixed at 20 V. 
 
Lipidomic data analysis— LC/MS (ESI+ and ESI− mode) data were processed using 
the XCMS [8] software to detect and align mzRT features. A feature is defined as a 
molecular entity with a unique m/z and a specific retention time. XCMS analysis of 
these data provided a matrix containing the retention time, m/z value, and integrated 
peak area of each feature for each sample of cells and culture medium. We constrained 
the initial number of features by means of the following criteria: only features above an 
intensity threshold of 3,400 counts were retained for further statistical analysis. Quality 
control samples (QCs) consisting of pooled cells from each condition were injected at 
the beginning and periodically every four samples. The performance of the LC/MS 
platform for each mzRT feature detected in the cell culture samples was assessed by 
calculating the relative standard deviation of these features on pooled samples (CVQC), 
following Vinaixa et al. [9]. Next, the intensities of the mzRT features were compared 
using a One-way ANOVA for each differentiation day separately, correcting for 
multiple testing using Tukey's ‘Honest Significant Difference’ method. Differentially 
regulated lipids (p value<0.05 and fold>2) were retained for further tandem MS 
characterization. Lipid structures were identified by matching tandem MS spectra 
against reference standards in HMDB [10], LIPIDMAPS [11] or LipidBlast [12] 
databases, or using CFM-ID software [13]. 
 
Abbreviations 
(AEBSF) 4-(2-aminoethyl) benzenesulfonyl fluoride, (ASC) adipose-derived stem cells, 
(BSA) bovine serum albumin, (DTT) dithiothreitol, 1-methyl-3-isobutylxanthine 
(IBMX), 
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ESM Table 1. Characteristics of the cohorts for the study of the mRNA (A) and protein 
(B) expression. 
 
A. Normoweight Obesity T2DM  
N 17 43 11  
Age (yr) [mean (SD)] 53.88 ± 15.41 57.23 ±14.08 66.09± 8.58  
Sex (N, Female) 12 25 5  
BMI (kg/m2) [median (IQR)] 23.81 (1.50) 27.99 (4.60)*** 28.68 (3.53)***  
HOMA-IR [median (IQR)] 0.82 (1.41) 1.22 (1.20) 3.66 (21.95)*  
Glucose (mM) [median (IQR)] 4.74 (0.80) 5.53 (0.64) 8.33 (3.11)***  
Insulin (µIU/mL) [median (IQR)] 3.57 (5.55) 4.49 (4.20) 10.23 (17.96)  
Triacylglycerol (mM)  
[median (IQR)] 
1.04 (0.87) 1.03 (0.76) 1.66 (1.08)  
NEFA  (mM) [mean (SD)] 1.00 ± 0.75 0.77 ± 0.26 0.92 ± 0.41  
Glycerol (mM) [median (IQR)] 177.6 (239.1) 144.3 (132.4) 301.6 (255.8)*  
 
B. Normoweight Obesity T2DM 
N 9 10 9 
Age (yr) [mean (SD)] 51.67 ± 3.24 52.70 ± 4.24 55.22 ± 4.84 
BMI (kg/m2) [median (IQR)] 23.30 (3.91) 33.48 (5.32)*** 35.22 (6.17)*** 
HOMA-IR [median (IQR)] 0.63 (1.38) 2.21 (3.08) 6.92 (7.30)** 
Glucose (mM) [median (IQR)] 3.78 (1.11) 4.28 (1.67) 8.56 (4.82)** 
Insulin (µIU/mL) [median (IQR)] 4.00 (5.03) 12.70 (12.21) 18.73 (12.32)** 
Triecylglycerol (mM)  
[median (IQR)] 
0.81 (0.82) 1.43 (1.25) 1.72 (1.60)* 
 
 
Abdominal adipose tissue (AT) was extracted from a cohort of 71 and 28 subjects for 
the gene (A) and protein (B) expression analysis, respectively. Participants	 were	grouped	by	BMI	and	type	2	diabetes	(T2D).	Clinical and anthropometrical variables 
were collected. Normal distributed data are expressed as mean value (SD), and for 
variables with no Gaussian distribution, values are expressed as median (interquartil 
range, IQR). *p<0.05, **p<0.01, ***p<0.001. 
 
ESM	Table	2.	Commercial	reagents	used	in	this	study.		A.	siRNA	OLIGONUCLEOTIDES	 	Symbol	 	 Company	 Reference	
⎯	⎯	⎯	⎯	⎯	⎯	⎯	Silencer(R)	Select	Pre-designed	siRNA	⎯	⎯	⎯	⎯	⎯	⎯	⎯	⎯	
LPIN1	 	 Ambion	 S23205,	S23206	
LPIN2	 	 Ambion	 S18590,	S18591	
LPIN3	 	 Ambion	 S35072,	S35073	Non-Targeting	control	 Ambion	 No.	1	
⎯	⎯	⎯	⎯	⎯	⎯	⎯	⎯	⎯	⎯	On-Target	Plus	siRNA	⎯	⎯	⎯	⎯	⎯	⎯	⎯	⎯	⎯	⎯	
LPIN1	 	 Dharmacon	 J-017427-09,	-11	
LPIN2	 	 Dharmacon	 J-013458-09,	-11	
LPIN3	 	 Dharmacon	 J-032702-07,	-08	Non-Targeting	control	 Dharmacon	 D-001810-01		B.	ANTIBODIES	 	Symbol	 Company	Refere ce	 Dilution	ACTIN	 Sigma-Aldrich	 A2228	 1/1000	CALNEXIN	 Abcam	 ab22595	 1/3000	GAPDH	 Santa	Cruz	Biotechnology	 sc-32233	 1/400	PPARG	 Cell	Signaling	 2443	 1/1000	SREBP1c	 Santa	Cruz	Biotechnology	 sc-8984	 1/1000	TUBULIN	 Sigma-Aldrich	 T6557	 1/3000	
⎯	⎯	⎯	⎯	⎯	⎯HRP-conjugated	secondary	antibodies	against	⎯	⎯	⎯	⎯	⎯	⎯		goat	 Sigma-Aldrich	 A8919	 1/4000	mouse	 Jackson	Immunoresearch	 115-035-008	 1/7000	rabbit	 Sigma-Aldrich	 A0545	 1/5000		C.	HYDROLYSIS	PROBES		Symbol	 Gene	 ID	 CQ	(mean	±	SD)	a	
ACACA	 acetyl-CoA	carboxylase	alpha	 Hs01046047_m1	 27.8	±	0.4	
AGPAT2	 1-acylglycerol-3-phosphate	O-acyltransferase	2	 Hs00944961_m1	 25.8	±	1.6	
CEBPA	 CCAAT/enhancer	binding	protein	(C/EBP),	alpha	 Hs00269972_s1	 22.5	±	1.3	
CEBPB	 CCAAT/enhancer	binding	protein	(C/EBP),	beta	 Hs00270923_s1	 22.5	±	0.1#	
CEBPD	 CCAAT/enhancer	binding	protein	(C/EBP),	delta	 Hs00270931_s1	 29.4	±	0.2#	
DGAT1	 diacylglycerol	acyltransferase	1	 Hs00201385_m1	 26.6	±	1.3	
DGAT2	 diacylglycerol	acyltransferase	2	 Hs00261438_m1	 20.9	±	0.6	
GPAT3	 glycerol-3-phosphate	 Hs00262010_m1	 26.8	±	1.0	
acyltransferase	3	
LPIN1	 lipin	1	 Hs00299515_m1	 23.2	±	0.4	
LPIN2	 lipin	2	 Hs00206237_m1	 27.4	±	0.3	
LPIN3	 lipin	3	 Hs01040129_m1	 25.0	±	0.4	
LPP1	 phosphatidate	phosphatase	type	2A	 Hs00170356_m1	 23.0	±	0.3	
LPP2	 phosphatidate	phosphatase	type	2C	 Hs00186575_m1	 28.4	±	6.2	
LPP3	 phosphatidate	phosphatase	type	2B	 Hs00170359_m1	 25.7	±	5.1	
MOGAT1	 monoacylglycerol	O-acyltransferase	1	 Hs00369695_m1	 34.6	±	1.8	
MOGAT2	 monoacylglycerol	O-acyltransferase	2	 Hs00228268_m1	 34.6	±	0.9	
MOGAT3	 monoacylglycerol	O-acyltransferase	3	 Hs00698325_m1	 Non	detectable	
PCK1	 phosphoenolpyruvate	carboxykinase	1	 Hs00159918_m1	 20.4	±	0.5	
PPARG	 peroxisome	proliferator-activated	receptor	gamma	 Hs00234592_m1	 23.2	±	0.4	
PPIA	 cyclophilin	1A	 Hs99999904_m1	 19.9	±	0.5	
SREBF1	 sterol	regulatory	element	binding	transcription	factor	1	 Hs01088691_m1	 22.1	±	0.6			amean	 CQ	 ±	 SD	 from	 the	 day	 10-control	 (non-targeting	 siRNA	 control	 of	 single	knockdowns),	except	#,	which	stands	for	day	4-control.		
 
 
 
ESM Fig. 1. Lipin expression levels in human adipocytes. (a-c) Relative mRNA levels 
of the lipin family members were quantified in human abdominal visceral adipose 
tissue. Participants were grouped by BMI and type 2 diabetes (T2D). *, p<0.05 vs. 
normoweight; ANOVA	and	Kruskal-Wallis	tests. (d) Protein levels of the lipin 
members were analysed during adipogenesis of adipose derived stem cells (ASC) from 
three different individuals. Protein levels of adipocyte markers (PPAR gamma and 
FABP4), and loading controls (glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 
and actin), were also analysed. Portions of blots from a representative sample are 
shown. (e) Subcellular fractions containing cytosolic, intranuclear and membrane 
protein were isolated from SGBS adipocytes (day 10 after differentiation), and 
subcellular localization of endogenous lipin-1, -2 and -3 was assessed. Equal protein 
amounts from the fractions were loaded on an 8% SDS-PAGE and immunoblotted 
using the indicated antibodies. Markers for cytosol (GAPDH), nuclei (tubulin), and 
membranes (calnexin) were used. Representative portions of Western blots with 
duplicates are shown. (f) Single lipin-1, -2 or -3 knockdowns (L1, L2, or L3 
respectively), and the non-targeting control (nT), were performed in SGBS preadipocyte 
cells. After induction of adipogenesis, cells were collected at day 4 and protein levels of 
lipins were analysed. Portions of blots from a representative sample are shown. 
 
 
 
ESM Fig. 2. The three members of the lipin family have a role in human SGBS 
lipogenesis in early adipogenesis stages. Knockdowna of single lipin members were 
performed in SGBS preadipocyte cells. After induction of adipogenesis, cells were 
collected at day 4 and analysed. (a) Protein levels of transcription factors (n=7), and (b) 
representative portions of Western blots are shown. Abundance of significantly changed 
species of (c) diacylglycerol (DG) and (d) triacylglycerol (TG), (n=4). Data	represent	mean±SD	 of	 fold	 increase	 over	 non-targeting	 controls	 (set	 as	 1).	 **p<0.01,	***p<0.001,	General	Lineal	Model	Univariate	 test.	White	bars,	LPIN1	 knockdown;	grey	bars,	LPIN2	knockdown;	black	bars,	LPIN3	knockdown. 
 
  
 
ESM Fig. 3. Transcript and protein levels in lipin- depleted SGBS preadipocytes after 
fully differentiation. Single knockdowns of lipin members were performed in SGBS 
preadipocyte cells. (a) At day 10 after differentiation, protein levels of the lipin family 
and adipocyte markers (PPAR gamma and SREBP1) were analysed. Portions of blots 
from a representative sample are shown. (b) Protein levels of transcription factors PPAR 
gamma and SREBP1 (n=5). (c) Transcript levels of genes involved in lipogenesis. Data	represent	mean±SD	of	fold	increase	over	non-targeting	controls	(set	as	1).	*p<0.05,	**p<0.01,	 ***p<0.001,	 General	 Lineal	 Model	 Univariate	 test.	 White	 bars,	 LPIN1	knockdown;	grey	bars,	LPIN2	knockdown;	black	bars,	LPIN3	knockdown. 
  
 
 
ESM Fig 4. Combinatorial depletion of lipins in SGBS preadipocytes after fully 
differentiation. LPIN1	and	LPIN2	double	knockdown	(L12),	LPIN1	and	LPIN3	double	knockdown	 (L13),	LPIN2	 and	LPIN3	 double	knockdown	 (L23),	 triple	knockdown 
(L123), and their corresponding non-targeting controls (nT), were performed in SGBS 
preadipocyte cells. Cells were induced to differentiate, and collected at day 10. 
Representative portions of Western blots are shown.  
 
 
 
ESM Fig 5. The LPP family is induced under conditions of repressed lipin expression. 
Knockdown of single lipin members were performed in SGBS preadipocyte cells and 
cells were induced to differentiate. (a) Transcript levels of genes from the LPP/PAP2 
family were analysed at day 4 after differentitation, relative to cyclophilin 1A and to 
control (n=3). (b, c) Single lipin knockdowns, and the corresponding non-targeting 
control, were performed in SGBS preadipocyte cells by using siRNA from two different 
sources and cells were collected on day 4 after differentiation. (b) Representative 
portions of Western blots of extracts from cells transfected with siRNA from 
Dharmacon (non targeting control, nT; single LPIN1, L1; LPIN2, L2; LPIN3, L3 
knockdowns). (c) Transcript levels of cells transfected with LPIN1 siRNA from both 
Dharmacon and Ambion were analysed (n=3-4). (d) SGBS preadipocytes were induced 
to differentiate in presence of 100 µmol/l propranolol (PrPol). Contrast-phase 
microscopy showed lipid droplet formation throughout adipogenesis is blocked in 
propranolol-treated cells.	 Data	 represent	 mean±SD	 of	 fold	 increase	 over	 non-
targeting	 controls	 (set	 as	 1).	 **p<0.01,	 ***p<0.001,	 General	 Lineal	 Model	Univariate	 test.	 (a)	White	 bars,	LPIN1	 knockdown;	 grey	bars,	LPIN2	 knockdown;	black	 bars,	 LPIN3	 knockdown.	 (c)	 White	 bars,	 Dharmacon	 siRNAs;	 black	 bars,	Ambion	siRNAs. 
  
